Our client needed to optimise adherence and persistence amongst patients who had been prescribed their self-injectable biologic.
They wanted a way to do this that would be more effective than just the features offered in a standard patient support app.
We proposed PERSIGNIA™, our digital, personalised medication support programme utilising NICE best practice. PERSIGNIA™ delivers an evidence-based approach to identify and address patients’ perceptions and practicalities that impede patient adherence to prescribed medication.
The PERSIGNIA™ programme was integrated into the clients’ app to screen and identify patients at risk. Having identified 30% of patients with one or more risk factors, PERSIGNIA™ then gave tailored support to each of these patients to help them overcome emotional and practical barriers.
PERSIGNIA™ was effective at reducing risks by:
of patients no longer had doubts about their personal need for the treatment.
of initial concerns about treatment were resolved.
reduction in initial practical barriers to treatment.